Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection
OnabotulinumtoxinA is used as treatment for refractory idiopathic and neurogenic detrusor overactivity in children. Many patients perform intermittent self-catheterization and therefore have higher rates of asymptomatic bacteriuria, which may increase their risk of symptomatic urinary tract infectio...
Gespeichert in:
Veröffentlicht in: | Journal of pediatric urology 2023-12, Vol.19 (6), p.742.e1-742.e8 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 742.e8 |
---|---|
container_issue | 6 |
container_start_page | 742.e1 |
container_title | Journal of pediatric urology |
container_volume | 19 |
creator | Bachtel, Hannah Agard Flores, Hunter Park, Bridget Kim, Soo Jeong Koh, Chester J. Janzen, Nicolette K. |
description | OnabotulinumtoxinA is used as treatment for refractory idiopathic and neurogenic detrusor overactivity in children. Many patients perform intermittent self-catheterization and therefore have higher rates of asymptomatic bacteriuria, which may increase their risk of symptomatic urinary tract infection (UTI) following treatment. Multiple injections are often needed due to the short-term efficacy of onabotulinumtoxinA treatment, which may also increase the risk of UTI.
We aim to evaluate whether a sterile urinary tract is necessary to decrease the risk of postoperative UTI in pediatric patients treated with onabotulinumtoxinA.
A retrospective review of patients undergoing intradetrusor onabotulinumtoxinA injection from 2014 to 2021 was performed. Demographic data, clinical characteristics, antibiotic treatment and culture results were collected. A positive urine culture was defined as ≥ 103 CFU/ml of uropathogenic bacteria. Our primary outcome was symptomatic UTI within 14 days of the procedure.
103 patients underwent 158 treatments with onabotulinumtoxinA. The incidence of postoperative UTI was 3.2%. The incidence of symptomatic postoperative UTI in patients with asymptomatic bacteriuria compared to those with sterile urine was not significantly different (3.8% vs 0%, p = 0.57). Obtaining a preoperative urinalysis or urine culture did not affect the incidence of postoperative UTI (p = 0.54). The number needed to treat with antibiotics to prevent one postoperative UTI was 27. The incidence of postoperative UTI was highest in patients with low-risk bladders (p = 0.043). Prior history of multi-drug resistant UTI was a risk factor for postoperative UTI (p = 0.048).
For children undergoing onabotulinumtoxinA injection, there are no evidence-based recommendations regarding antibiotic prophylaxis and the need to screen for and treat asymptomatic bacteruria prior to treatment. Our study addresses this important clinical question, and shows no difference in the rate of postoperative UTI between patients with asymptomatic bacteriuria and those with sterile urine. Patients with a history of multi-drug resistant UTI are at increased risk of symptomatic postoperative UTI and may benefit from preoperative urine testing and treatment. Limitations of our retrospective study include its small sample size in the face of such a low incidence of our primary outcome.
The risk of UTI following onabotulinumtoxinA injection in children is low. The presence of sterile urine at the t |
doi_str_mv | 10.1016/j.jpurol.2023.05.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2846925188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1477513123002115</els_id><sourcerecordid>2846925188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-7ffb6f3191dfcdec34ea2c5d450d34b22de15834747278c8fc17003b85a819d23</originalsourceid><addsrcrecordid>eNp9kcuOFSEQhonROOPoGxjD0k23XLoP9MZkMhkvySSz0TWhofocOjQcuYzO6_ikcnJGly4oCvJV_VA_Qm8p6Smhuw9rvx5rir5nhPGejD0h8hm6pFLwbpCTfN7yQYhupJxeoFc5r4RwQdj0El1wMbZ0opfo9-2D9lUXF_a4HADX4rwrjzguOMV2CO0qnaKpvtQEWAfbVnGzi8UZXBLoskEo2AVsDs7bBAH_dOWAA7Tn7SE0avbaWki4hhb38STmQknaQkk1x4Tvg55jqd6FupX4y4XrBqxgiovhNXqxaJ_hzdN-hb5_uv1286W7u__89eb6rjOc0tKJZZl3C6cTtYuxYPgAmpnRDiOxfJgZs0BHyQcxCCakkYuhok1klqOWdLKMX6H3577HFH9UyEVtLhvwXgeINSsmh93ERiplQ4czalLMOcGijsltOj0qStTJHbWqszvq5I4io2rutLJ3Twp13sD-K_prRwM-ngFo_3xwkFQ2DoIB61IbhrLR_V_hD5-MqKE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2846925188</pqid></control><display><type>article</type><title>Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bachtel, Hannah Agard ; Flores, Hunter ; Park, Bridget ; Kim, Soo Jeong ; Koh, Chester J. ; Janzen, Nicolette K.</creator><creatorcontrib>Bachtel, Hannah Agard ; Flores, Hunter ; Park, Bridget ; Kim, Soo Jeong ; Koh, Chester J. ; Janzen, Nicolette K.</creatorcontrib><description>OnabotulinumtoxinA is used as treatment for refractory idiopathic and neurogenic detrusor overactivity in children. Many patients perform intermittent self-catheterization and therefore have higher rates of asymptomatic bacteriuria, which may increase their risk of symptomatic urinary tract infection (UTI) following treatment. Multiple injections are often needed due to the short-term efficacy of onabotulinumtoxinA treatment, which may also increase the risk of UTI.
We aim to evaluate whether a sterile urinary tract is necessary to decrease the risk of postoperative UTI in pediatric patients treated with onabotulinumtoxinA.
A retrospective review of patients undergoing intradetrusor onabotulinumtoxinA injection from 2014 to 2021 was performed. Demographic data, clinical characteristics, antibiotic treatment and culture results were collected. A positive urine culture was defined as ≥ 103 CFU/ml of uropathogenic bacteria. Our primary outcome was symptomatic UTI within 14 days of the procedure.
103 patients underwent 158 treatments with onabotulinumtoxinA. The incidence of postoperative UTI was 3.2%. The incidence of symptomatic postoperative UTI in patients with asymptomatic bacteriuria compared to those with sterile urine was not significantly different (3.8% vs 0%, p = 0.57). Obtaining a preoperative urinalysis or urine culture did not affect the incidence of postoperative UTI (p = 0.54). The number needed to treat with antibiotics to prevent one postoperative UTI was 27. The incidence of postoperative UTI was highest in patients with low-risk bladders (p = 0.043). Prior history of multi-drug resistant UTI was a risk factor for postoperative UTI (p = 0.048).
For children undergoing onabotulinumtoxinA injection, there are no evidence-based recommendations regarding antibiotic prophylaxis and the need to screen for and treat asymptomatic bacteruria prior to treatment. Our study addresses this important clinical question, and shows no difference in the rate of postoperative UTI between patients with asymptomatic bacteriuria and those with sterile urine. Patients with a history of multi-drug resistant UTI are at increased risk of symptomatic postoperative UTI and may benefit from preoperative urine testing and treatment. Limitations of our retrospective study include its small sample size in the face of such a low incidence of our primary outcome.
The risk of UTI following onabotulinumtoxinA injection in children is low. The presence of sterile urine at the time of surgery does not significantly decrease the risk of postoperative UTI. Routine treatment of asymptomatic bacteriuria prior to surgery results in a large number of patients receiving unnecessary antibiotics. As a result, we recommend against preoperative urine testing for most asymptomatic patients.Summary TablePatient characteristics and relationship to symptomatic postoperative UTI.Summary TableNo UTI (N = 153)Symptomatic UTI (N = 5)P-valueAge at surgery, median (IQR)13 (8.5–16.6) yrs13.3 (11.6–14.9) yrs0.87Gender, Female50% (77/153)60% (3/5)0.67Spina Bifida60% (92/153)80% (4/5)0.37Urinary incontinence72% (110/153)80% (4/5)0.69Recurrent UTI17% (27/153)40% (2/5)0.20Clean intermittent catheterization (CIC)89% (136/153)80% (4/5)0.54Continuous antibiotic prophylaxis (CAP)16% (25/153)0% (0/5)0.32History of multi-drug resistant UTIYes 21% (15/71)Yes 60% (3/5)0.048No 79% (56/71)No 40% (2/5)Unknown 54% (82/153)Vesicoureteral refluxYes 17% (22/127)Yes 20% (1/5)0.88No 83% (105/127)No 80% (4/5)Unknown 17% (26/153)History of prior onabotulinumtoxinA injection43% (66/153)80% (4/5)0.10Bladder risk categorizationLow 9% (13/144)Low 40% (2/5)0.043Intermediate 34% (49/144)Hostile 57% (82/144)Hostile 60% (3/5)Unknown 6% (9/153)Preoperative urinalysis or urine culture performed11% (17/153)20% (1/5)0.54Positive preoperative urine culture43% (6/14)100% (1/1)0.27Positive intraoperative urine cultureYes 76% (100/131)Yes 100% (4/4)No 0% (0/4)Unknown 20% (1/5)0.57No 24% (31/131)Unknown 14% (22/153)IV antibiotic prophylaxis at time of surgery95% (145/153)80% (4/5)0.16Empiric treatment with oral antibiotics∗15% (23/153)0% (0/5)0.35∗Refers to asymptomatic patients who were treated empirically with a treatment course of antibiotics within 7 days before or after their Botox procedure.</description><identifier>ISSN: 1477-5131</identifier><identifier>EISSN: 1873-4898</identifier><identifier>DOI: 10.1016/j.jpurol.2023.05.008</identifier><identifier>PMID: 37537091</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotic prophylaxis ; Bacteriuria - diagnosis ; Bacteriuria - drug therapy ; Bacteriuria - etiology ; Botulinum Toxins, Type A ; Child ; Humans ; Pediatrics ; Postoperative Complications ; Retrospective Studies ; Urinalysis ; Urinary Bladder, Neurogenic - complications ; Urinary Bladder, Neurogenic - drug therapy ; Urinary tract infections ; Urinary Tract Infections - diagnosis ; Urinary Tract Infections - drug therapy ; Urinary Tract Infections - etiology ; Urology</subject><ispartof>Journal of pediatric urology, 2023-12, Vol.19 (6), p.742.e1-742.e8</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c311t-7ffb6f3191dfcdec34ea2c5d450d34b22de15834747278c8fc17003b85a819d23</cites><orcidid>0000-0001-6342-6955 ; 0000-0002-7915-0858 ; 0000-0002-9276-8433</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37537091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bachtel, Hannah Agard</creatorcontrib><creatorcontrib>Flores, Hunter</creatorcontrib><creatorcontrib>Park, Bridget</creatorcontrib><creatorcontrib>Kim, Soo Jeong</creatorcontrib><creatorcontrib>Koh, Chester J.</creatorcontrib><creatorcontrib>Janzen, Nicolette K.</creatorcontrib><title>Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection</title><title>Journal of pediatric urology</title><addtitle>J Pediatr Urol</addtitle><description>OnabotulinumtoxinA is used as treatment for refractory idiopathic and neurogenic detrusor overactivity in children. Many patients perform intermittent self-catheterization and therefore have higher rates of asymptomatic bacteriuria, which may increase their risk of symptomatic urinary tract infection (UTI) following treatment. Multiple injections are often needed due to the short-term efficacy of onabotulinumtoxinA treatment, which may also increase the risk of UTI.
We aim to evaluate whether a sterile urinary tract is necessary to decrease the risk of postoperative UTI in pediatric patients treated with onabotulinumtoxinA.
A retrospective review of patients undergoing intradetrusor onabotulinumtoxinA injection from 2014 to 2021 was performed. Demographic data, clinical characteristics, antibiotic treatment and culture results were collected. A positive urine culture was defined as ≥ 103 CFU/ml of uropathogenic bacteria. Our primary outcome was symptomatic UTI within 14 days of the procedure.
103 patients underwent 158 treatments with onabotulinumtoxinA. The incidence of postoperative UTI was 3.2%. The incidence of symptomatic postoperative UTI in patients with asymptomatic bacteriuria compared to those with sterile urine was not significantly different (3.8% vs 0%, p = 0.57). Obtaining a preoperative urinalysis or urine culture did not affect the incidence of postoperative UTI (p = 0.54). The number needed to treat with antibiotics to prevent one postoperative UTI was 27. The incidence of postoperative UTI was highest in patients with low-risk bladders (p = 0.043). Prior history of multi-drug resistant UTI was a risk factor for postoperative UTI (p = 0.048).
For children undergoing onabotulinumtoxinA injection, there are no evidence-based recommendations regarding antibiotic prophylaxis and the need to screen for and treat asymptomatic bacteruria prior to treatment. Our study addresses this important clinical question, and shows no difference in the rate of postoperative UTI between patients with asymptomatic bacteriuria and those with sterile urine. Patients with a history of multi-drug resistant UTI are at increased risk of symptomatic postoperative UTI and may benefit from preoperative urine testing and treatment. Limitations of our retrospective study include its small sample size in the face of such a low incidence of our primary outcome.
The risk of UTI following onabotulinumtoxinA injection in children is low. The presence of sterile urine at the time of surgery does not significantly decrease the risk of postoperative UTI. Routine treatment of asymptomatic bacteriuria prior to surgery results in a large number of patients receiving unnecessary antibiotics. As a result, we recommend against preoperative urine testing for most asymptomatic patients.Summary TablePatient characteristics and relationship to symptomatic postoperative UTI.Summary TableNo UTI (N = 153)Symptomatic UTI (N = 5)P-valueAge at surgery, median (IQR)13 (8.5–16.6) yrs13.3 (11.6–14.9) yrs0.87Gender, Female50% (77/153)60% (3/5)0.67Spina Bifida60% (92/153)80% (4/5)0.37Urinary incontinence72% (110/153)80% (4/5)0.69Recurrent UTI17% (27/153)40% (2/5)0.20Clean intermittent catheterization (CIC)89% (136/153)80% (4/5)0.54Continuous antibiotic prophylaxis (CAP)16% (25/153)0% (0/5)0.32History of multi-drug resistant UTIYes 21% (15/71)Yes 60% (3/5)0.048No 79% (56/71)No 40% (2/5)Unknown 54% (82/153)Vesicoureteral refluxYes 17% (22/127)Yes 20% (1/5)0.88No 83% (105/127)No 80% (4/5)Unknown 17% (26/153)History of prior onabotulinumtoxinA injection43% (66/153)80% (4/5)0.10Bladder risk categorizationLow 9% (13/144)Low 40% (2/5)0.043Intermediate 34% (49/144)Hostile 57% (82/144)Hostile 60% (3/5)Unknown 6% (9/153)Preoperative urinalysis or urine culture performed11% (17/153)20% (1/5)0.54Positive preoperative urine culture43% (6/14)100% (1/1)0.27Positive intraoperative urine cultureYes 76% (100/131)Yes 100% (4/4)No 0% (0/4)Unknown 20% (1/5)0.57No 24% (31/131)Unknown 14% (22/153)IV antibiotic prophylaxis at time of surgery95% (145/153)80% (4/5)0.16Empiric treatment with oral antibiotics∗15% (23/153)0% (0/5)0.35∗Refers to asymptomatic patients who were treated empirically with a treatment course of antibiotics within 7 days before or after their Botox procedure.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic prophylaxis</subject><subject>Bacteriuria - diagnosis</subject><subject>Bacteriuria - drug therapy</subject><subject>Bacteriuria - etiology</subject><subject>Botulinum Toxins, Type A</subject><subject>Child</subject><subject>Humans</subject><subject>Pediatrics</subject><subject>Postoperative Complications</subject><subject>Retrospective Studies</subject><subject>Urinalysis</subject><subject>Urinary Bladder, Neurogenic - complications</subject><subject>Urinary Bladder, Neurogenic - drug therapy</subject><subject>Urinary tract infections</subject><subject>Urinary Tract Infections - diagnosis</subject><subject>Urinary Tract Infections - drug therapy</subject><subject>Urinary Tract Infections - etiology</subject><subject>Urology</subject><issn>1477-5131</issn><issn>1873-4898</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcuOFSEQhonROOPoGxjD0k23XLoP9MZkMhkvySSz0TWhofocOjQcuYzO6_ikcnJGly4oCvJV_VA_Qm8p6Smhuw9rvx5rir5nhPGejD0h8hm6pFLwbpCTfN7yQYhupJxeoFc5r4RwQdj0El1wMbZ0opfo9-2D9lUXF_a4HADX4rwrjzguOMV2CO0qnaKpvtQEWAfbVnGzi8UZXBLoskEo2AVsDs7bBAH_dOWAA7Tn7SE0avbaWki4hhb38STmQknaQkk1x4Tvg55jqd6FupX4y4XrBqxgiovhNXqxaJ_hzdN-hb5_uv1286W7u__89eb6rjOc0tKJZZl3C6cTtYuxYPgAmpnRDiOxfJgZs0BHyQcxCCakkYuhok1klqOWdLKMX6H3577HFH9UyEVtLhvwXgeINSsmh93ERiplQ4czalLMOcGijsltOj0qStTJHbWqszvq5I4io2rutLJ3Twp13sD-K_prRwM-ngFo_3xwkFQ2DoIB61IbhrLR_V_hD5-MqKE</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Bachtel, Hannah Agard</creator><creator>Flores, Hunter</creator><creator>Park, Bridget</creator><creator>Kim, Soo Jeong</creator><creator>Koh, Chester J.</creator><creator>Janzen, Nicolette K.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6342-6955</orcidid><orcidid>https://orcid.org/0000-0002-7915-0858</orcidid><orcidid>https://orcid.org/0000-0002-9276-8433</orcidid></search><sort><creationdate>202312</creationdate><title>Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection</title><author>Bachtel, Hannah Agard ; Flores, Hunter ; Park, Bridget ; Kim, Soo Jeong ; Koh, Chester J. ; Janzen, Nicolette K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-7ffb6f3191dfcdec34ea2c5d450d34b22de15834747278c8fc17003b85a819d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic prophylaxis</topic><topic>Bacteriuria - diagnosis</topic><topic>Bacteriuria - drug therapy</topic><topic>Bacteriuria - etiology</topic><topic>Botulinum Toxins, Type A</topic><topic>Child</topic><topic>Humans</topic><topic>Pediatrics</topic><topic>Postoperative Complications</topic><topic>Retrospective Studies</topic><topic>Urinalysis</topic><topic>Urinary Bladder, Neurogenic - complications</topic><topic>Urinary Bladder, Neurogenic - drug therapy</topic><topic>Urinary tract infections</topic><topic>Urinary Tract Infections - diagnosis</topic><topic>Urinary Tract Infections - drug therapy</topic><topic>Urinary Tract Infections - etiology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bachtel, Hannah Agard</creatorcontrib><creatorcontrib>Flores, Hunter</creatorcontrib><creatorcontrib>Park, Bridget</creatorcontrib><creatorcontrib>Kim, Soo Jeong</creatorcontrib><creatorcontrib>Koh, Chester J.</creatorcontrib><creatorcontrib>Janzen, Nicolette K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pediatric urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bachtel, Hannah Agard</au><au>Flores, Hunter</au><au>Park, Bridget</au><au>Kim, Soo Jeong</au><au>Koh, Chester J.</au><au>Janzen, Nicolette K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection</atitle><jtitle>Journal of pediatric urology</jtitle><addtitle>J Pediatr Urol</addtitle><date>2023-12</date><risdate>2023</risdate><volume>19</volume><issue>6</issue><spage>742.e1</spage><epage>742.e8</epage><pages>742.e1-742.e8</pages><issn>1477-5131</issn><eissn>1873-4898</eissn><abstract>OnabotulinumtoxinA is used as treatment for refractory idiopathic and neurogenic detrusor overactivity in children. Many patients perform intermittent self-catheterization and therefore have higher rates of asymptomatic bacteriuria, which may increase their risk of symptomatic urinary tract infection (UTI) following treatment. Multiple injections are often needed due to the short-term efficacy of onabotulinumtoxinA treatment, which may also increase the risk of UTI.
We aim to evaluate whether a sterile urinary tract is necessary to decrease the risk of postoperative UTI in pediatric patients treated with onabotulinumtoxinA.
A retrospective review of patients undergoing intradetrusor onabotulinumtoxinA injection from 2014 to 2021 was performed. Demographic data, clinical characteristics, antibiotic treatment and culture results were collected. A positive urine culture was defined as ≥ 103 CFU/ml of uropathogenic bacteria. Our primary outcome was symptomatic UTI within 14 days of the procedure.
103 patients underwent 158 treatments with onabotulinumtoxinA. The incidence of postoperative UTI was 3.2%. The incidence of symptomatic postoperative UTI in patients with asymptomatic bacteriuria compared to those with sterile urine was not significantly different (3.8% vs 0%, p = 0.57). Obtaining a preoperative urinalysis or urine culture did not affect the incidence of postoperative UTI (p = 0.54). The number needed to treat with antibiotics to prevent one postoperative UTI was 27. The incidence of postoperative UTI was highest in patients with low-risk bladders (p = 0.043). Prior history of multi-drug resistant UTI was a risk factor for postoperative UTI (p = 0.048).
For children undergoing onabotulinumtoxinA injection, there are no evidence-based recommendations regarding antibiotic prophylaxis and the need to screen for and treat asymptomatic bacteruria prior to treatment. Our study addresses this important clinical question, and shows no difference in the rate of postoperative UTI between patients with asymptomatic bacteriuria and those with sterile urine. Patients with a history of multi-drug resistant UTI are at increased risk of symptomatic postoperative UTI and may benefit from preoperative urine testing and treatment. Limitations of our retrospective study include its small sample size in the face of such a low incidence of our primary outcome.
The risk of UTI following onabotulinumtoxinA injection in children is low. The presence of sterile urine at the time of surgery does not significantly decrease the risk of postoperative UTI. Routine treatment of asymptomatic bacteriuria prior to surgery results in a large number of patients receiving unnecessary antibiotics. As a result, we recommend against preoperative urine testing for most asymptomatic patients.Summary TablePatient characteristics and relationship to symptomatic postoperative UTI.Summary TableNo UTI (N = 153)Symptomatic UTI (N = 5)P-valueAge at surgery, median (IQR)13 (8.5–16.6) yrs13.3 (11.6–14.9) yrs0.87Gender, Female50% (77/153)60% (3/5)0.67Spina Bifida60% (92/153)80% (4/5)0.37Urinary incontinence72% (110/153)80% (4/5)0.69Recurrent UTI17% (27/153)40% (2/5)0.20Clean intermittent catheterization (CIC)89% (136/153)80% (4/5)0.54Continuous antibiotic prophylaxis (CAP)16% (25/153)0% (0/5)0.32History of multi-drug resistant UTIYes 21% (15/71)Yes 60% (3/5)0.048No 79% (56/71)No 40% (2/5)Unknown 54% (82/153)Vesicoureteral refluxYes 17% (22/127)Yes 20% (1/5)0.88No 83% (105/127)No 80% (4/5)Unknown 17% (26/153)History of prior onabotulinumtoxinA injection43% (66/153)80% (4/5)0.10Bladder risk categorizationLow 9% (13/144)Low 40% (2/5)0.043Intermediate 34% (49/144)Hostile 57% (82/144)Hostile 60% (3/5)Unknown 6% (9/153)Preoperative urinalysis or urine culture performed11% (17/153)20% (1/5)0.54Positive preoperative urine culture43% (6/14)100% (1/1)0.27Positive intraoperative urine cultureYes 76% (100/131)Yes 100% (4/4)No 0% (0/4)Unknown 20% (1/5)0.57No 24% (31/131)Unknown 14% (22/153)IV antibiotic prophylaxis at time of surgery95% (145/153)80% (4/5)0.16Empiric treatment with oral antibiotics∗15% (23/153)0% (0/5)0.35∗Refers to asymptomatic patients who were treated empirically with a treatment course of antibiotics within 7 days before or after their Botox procedure.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37537091</pmid><doi>10.1016/j.jpurol.2023.05.008</doi><orcidid>https://orcid.org/0000-0001-6342-6955</orcidid><orcidid>https://orcid.org/0000-0002-7915-0858</orcidid><orcidid>https://orcid.org/0000-0002-9276-8433</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1477-5131 |
ispartof | Journal of pediatric urology, 2023-12, Vol.19 (6), p.742.e1-742.e8 |
issn | 1477-5131 1873-4898 |
language | eng |
recordid | cdi_proquest_miscellaneous_2846925188 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Anti-Bacterial Agents - therapeutic use Antibiotic prophylaxis Bacteriuria - diagnosis Bacteriuria - drug therapy Bacteriuria - etiology Botulinum Toxins, Type A Child Humans Pediatrics Postoperative Complications Retrospective Studies Urinalysis Urinary Bladder, Neurogenic - complications Urinary Bladder, Neurogenic - drug therapy Urinary tract infections Urinary Tract Infections - diagnosis Urinary Tract Infections - drug therapy Urinary Tract Infections - etiology Urology |
title | Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A37%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20the%20utility%20of%20routine%20urine%20culture%20and%20antibiotic%20treatment%20in%20children%20with%20neurogenic%20bladder%20undergoing%20intradetrusor%20OnabotulinumtoxinA%20injection&rft.jtitle=Journal%20of%20pediatric%20urology&rft.au=Bachtel,%20Hannah%20Agard&rft.date=2023-12&rft.volume=19&rft.issue=6&rft.spage=742.e1&rft.epage=742.e8&rft.pages=742.e1-742.e8&rft.issn=1477-5131&rft.eissn=1873-4898&rft_id=info:doi/10.1016/j.jpurol.2023.05.008&rft_dat=%3Cproquest_cross%3E2846925188%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2846925188&rft_id=info:pmid/37537091&rft_els_id=S1477513123002115&rfr_iscdi=true |